Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome - PubMed (original) (raw)

. 2013 Jul 25;122(4):554-61.

doi: 10.1182/blood-2013-03-491936. Epub 2013 Jun 3.

Affiliations

• PMID: 23733339
• DOI: 10.1182/blood-2013-03-491936

Free article

Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome

Sergey I Nikolaev et al. Blood. 2013.

Free article

Abstract

Some neonates with Down syndrome (DS) are diagnosed with self-regressing transient myeloproliferative disorder (TMD), and 20% to 30% of those progress to acute megakaryoblastic leukemia (AMKL). We performed exome sequencing in 7 TMD/AMKL cases and copy-number analysis in these and 10 additional cases. All TMD/AMKL samples contained GATA1 mutations. No exome-sequenced TMD/AMKL sample had other recurrently mutated genes. However, 2 of 5 TMD cases, and all AMKL cases, showed mutations/deletions other than GATA1, in genes proven as transformation drivers in non-DS leukemia (EZH2, APC, FLT3, JAK1, PARK2-PACRG, EXT1, DLEC1, and SMC3). One patient at the TMD stage revealed 2 clonal expansions with different GATA1 mutations, of which 1 clone had an additional driver mutation. Interestingly, it was the other clone that gave rise to AMKL after accumulating mutations in 7 other genes. Data suggest that GATA1 mutations alone are sufficient for clonal expansions, and additional driver mutations at the TMD stage do not necessarily predict AMKL progression. Later in infancy, leukemic progression requires "third-hit driver" mutations/somatic copy-number alterations found in non-DS leukemias. Putative driver mutations affecting WNT (wingless-related integration site), JAK-STAT (Janus kinase/signal transducer and activator of transcription), or MAPK/PI3K (mitogen-activated kinase/phosphatidylinositol-3 kinase) pathways were found in all cases, aberrant activation of which converges on overexpression of MYC.

PubMed Disclaimer

Similar articles

• Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
  Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Greene ME, et al. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6. doi: 10.1016/j.bcmd.2003.08.001. Blood Cells Mol Dis. 2003. PMID: 14636651
• Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
  Kanegane H, Watanabe S, Nomura K, Xu G, Ito E, Miyawaki T. Kanegane H, et al. Int J Hematol. 2007 Oct;86(3):250-2. doi: 10.1532/IJH97.07058. Int J Hematol. 2007. PMID: 17988992
• A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
  Haemmerling S, Behnisch W, Doerks T, Korbel JO, Bork P, Moog U, Hentze S, Grasshoff U, Bonin M, Rieß O, Janssen JW, Jauch A, Bartram CR, Reinhardt D, Koch KA, Bandapalli OR, Kulozik AE. Haemmerling S, et al. Br J Haematol. 2012 Apr;157(2):180-7. doi: 10.1111/j.1365-2141.2012.09028.x. Epub 2012 Feb 1. Br J Haematol. 2012. PMID: 22296450
• Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
  Roy A, Roberts I, Norton A, Vyas P. Roy A, et al. Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Br J Haematol. 2009. PMID: 19594743 Review.

Cited by

• Congenital leukemia: A case report and review of literature.
  Yang CX, Yang Y, Zhang FL, Wang DH, Bian QH, Zhou M, Zhou MX, Yang XY. Yang CX, et al. World J Clin Cases. 2023 Oct 16;11(29):7227-7233. doi: 10.12998/wjcc.v11.i29.7227. World J Clin Cases. 2023. PMID: 37946786 Free PMC article.
• GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.
  Takasaki K, Chou ST. Takasaki K, et al. Adv Exp Med Biol. 2024;1459:261-287. doi: 10.1007/978-3-031-62731-6_12. Adv Exp Med Biol. 2024. PMID: 39017848 Review.
• Down syndrome and leukemia: insights into leukemogenesis and translational targets.
  Mateos MK, Barbaric D, Byatt SA, Sutton R, Marshall GM. Mateos MK, et al. Transl Pediatr. 2015 Apr;4(2):76-92. doi: 10.3978/j.issn.2224-4336.2015.03.03. Transl Pediatr. 2015. PMID: 26835364 Free PMC article. Review.
• Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
  Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Bhatnagar N, et al. Curr Hematol Malig Rep. 2016 Oct;11(5):333-41. doi: 10.1007/s11899-016-0338-x. Curr Hematol Malig Rep. 2016. PMID: 27510823 Free PMC article. Review.
• Too many white cells-TAM, JMML, or something else?
  Satty A, Stieglitz E, Kucine N. Satty A, et al. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):37-42. doi: 10.1182/hematology.2023000464. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066851 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal